stockrow
Friday 6 November 2026
Export VIR’s income statement to Excel — free account
Vir Biotechnology, Inc.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +200.5%
Quarter to September 2026, against a year earlier
12.19
1.17
+10.62%
Follow VIR
Alert me
Vir Biotechnology, Inc. (VIR) P/E ratio
Vir Biotechnology, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 10.4× (December 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 6.4× | (38.81%) |
| FY2021 | 10.4× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 28 more quarters | Free account |
Against its own ten years
Low 0.0×
High 10.4×
Ten-year median
0.0×
Current reading's percentile
83
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MRVI Maravai LifeSciences Holdings, Inc. compare | n/m |
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| MESO Mesoblast Limited compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| VIR Vir Biotechnology, Inc. | n/m |
| TRAX First Tracks Biotherapeutics, Inc. compare | n/m |
| REPL Replimune Group, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | n/m |
| HRMY Harmony Biosciences Holdings, Inc. compare | 10.7× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)